---
title: "Genpharmasec Ltd (531592) — Share Price, Financials & Analysis"
symbol: "531592"
company: "Genpharmasec Ltd"
canonical: "https://tapetide.com/stocks/531592"
isin: "INE861N01036"
nse_symbol: "GENERICPHARMASECLTD"
bse_code: "531592"
sector: "Commercial Services"
industry: "Trading & Distributors"
market_cap_cr: 65.86
generated_at: "2026-09-13T19:40:00.760Z"
---

# Genpharmasec Ltd (531592)

Canonical page: https://tapetide.com/stocks/531592

## Company

- **NSE Symbol:** GENERICPHARMASECLTD
- **BSE Code:** 531592
- **ISIN:** INE861N01036
- **Sector:** Commercial Services
- **Industry:** Trading & Distributors
- **Macro Sector:** Services
- **Stock Type:** EQUITY
- **CEO:** Mr. Sohan Chaturvedi
- **Employees:** 10
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** genpharmasec.com

## About

Incorporated in 1992, Generic Pharmasec 
 Ltd deals in pharmaceutical activities /services and trades in equity shares[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:45:25.225320Z.

- **Market Cap:** ₹65.86 Cr
- **Classification:** Microcap
- **P/E (reported):** -116
- **EPS (TTM):** ₹0
- **EPS (reported):** ₹0
- **Book Value:** ₹1.2
- **Price to Book:** 0.97
- **Dividend Yield:** 0%
- **ROE:** 1.89%
- **ROCE:** 3.3%
- **Debt to Equity:** 0.53
- **Revenue (yearly):** ₹139.94 Cr
- **Net Income:** ₹-0.19 Cr
- **EBITDA:** ₹1.22 Cr
- **52-Week High:** ₹2.15
- **52-Week Low:** ₹0.75
- **RSI (14):** 59.69

## Tapetide Score

- **Score:** 46 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 31.9 (of 4473 scored stocks)
- **Confidence:** 91%
- **Data coverage:** 81%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 23.14 | 9% |
| growth | 98.9 | 9% |
| momentum | 77.59 | 12% |
| ownership | 50 | 24% |
| quality | 34.79 | 22% |
| valuation | 31.11 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.98 times its book value
- Company is expected to give good quarter
- Debtor days have improved from 111 to 76.3 days.
- Company's working capital requirements have reduced from 136 days to 61.1 days

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 30.0%
- Company has a low return on equity of 1.56% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.2.83 Cr.
- Promoter holding has decreased over last 3 years: -30.0%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 201.36% | 197.71% | -80.42% |
| ebitda margin growth | -56.67% | -90% | -62.39% | — |
| net income growth | -114.29% | -115.83% | 13% | — |
| revenue growth | -11.33% | 280.27% | 76% | — |
| roce | -71.67% | 243.75% | 73.68% | — |
| roe | -112.59% | -826.92% | 2.99% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 7.86 | 6.38 | 10.2 | 5.2 | 6.03 | 8.48 | 14.01 | 12.04 | 32.64 | 39.83 | 55.43 | 49.71 |
| Expenses | 7.89 | 6.37 | 10.21 | 5 | 5.9 | 7.76 | 15.01 | 11.1 | 33.1 | 41.07 | 53.44 | 48.75 |
| Operating Profit | -0.03 | 0.01 | -0.01 | 0.2 | 0.13 | 0.72 | -1 | 0.94 | -0.46 | -1.24 | 1.99 | 0.96 |
| OPM % | -0.38 | 0.16 | -0.1 | 3.85 | 2.16 | 8.49 | -7.14 | 7.81 | -1.41 | -3.11 | 3.59 | 1.93 |
| Other Income | 0.15 | 0.14 | 0.31 | 0.57 | 0.75 | 0.81 | 0.94 | 0.69 | 0.46 | 0.98 | 1.02 | 0.37 |
| Interest | 0.07 | 0 | 0.16 | 0.1 | 0.07 | 0.16 | 0.11 | 0.12 | 0.23 | 0.41 | 0.48 | 0.4 |
| Depreciation | 0 | 0.12 | 0.03 | 0.16 | 0.3 | 0.1 | 0.26 | 0.27 | 0.56 | 0.67 | 0.68 | 0.67 |
| Profit before tax | 0.05 | 0.03 | 0.11 | 0.51 | 0.51 | 1.27 | -0.43 | 1.24 | -0.79 | -1.34 | 1.85 | 0.26 |
| Tax % | 80 | -100 | 345.45 | 35.29 | -39.22 | 40.16 | -37.21 | 2.42 | 48.1 | -37.31 | 27.03 | 165.38 |
| Net Profit | 0.01 | 0.06 | -0.27 | 0.33 | 0.7 | 0.76 | -0.27 | 1.22 | -1.18 | -0.83 | 1.36 | -0.17 |
| EPS in Rs | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0 | 0.02 | -0.02 | -0.01 | 0.03 | 0 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- |
| Sales | 26 | 30 | 34 | 140 | 178 |
| Expenses | 25 | 30 | 33 | 139 | 176 |
| Operating Profit | 0 | 0 | 0 | 1 | 1 |
| OPM % | 1 | 0.1 | 0.2 | 0.9 | 0.7 |
| Other Income | 0 | 1 | 3 | 3 | 3 |
| Interest | 0 | 0 | 0 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 2 | 3 |
| Profit before tax | 0 | 0 | 2 | 1 | 0 |
| Tax % | -300 | 168 | 35 | 42 | — |
| Net Profit | 1 | 0 | 1 | 1 | -1 |
| EPS in Rs | 0.02 | 0 | 0.02 | 0.03 | 0 |
| Dividend Payout % | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | 28 | 55 | 55 | 55 |
| Reserves | -12 | 9 | 10 | 11 |
| Borrowings | 3 | 4 | 5 | 35 |
| Other Liabilities | 1 | 3 | 9 | 37 |
| Total Liabilities | 20 | 71 | 80 | 138 |
| Fixed Assets | 0 | 1 | 8 | 41 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 1 | 19 | 19 | 2 |
| Other Assets | 19 | 51 | 53 | 95 |
| Total Assets | 20 | 71 | 80 | 138 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | -3 | -3 | 3 | -18 |
| Cash from Investing Activity | 0 | -28 | -15 | 13 |
| Cash from Financing Activity | 3 | 48 | -1 | 4 |
| Net Cash Flow | 0 | 17 | -14 | 0 |
| Free Cash Flow | -3 | -3 | -3 | -21 |
| CFO/OP | -1277 | -7275 | 3825 | -1357 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Debtor Days | 82 | 109 | 148 | 76 |
| Inventory Days | 151 | 133 | 104 | 39 |
| Days Payable | 21 | 36 | 105 | 90 |
| Cash Conversion Cycle | 211 | 207 | 147 | 26 |
| Working Capital Days | 199 | 213 | 133 | 61 |
| ROCE % | — | 2 | 3 | 3 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 59.96% | 59.96% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 32.82% | 33.81% | 56.17% | 61.26% | 59.55% | 59.62% | 59.94% | 60.03% | 60.19% | 62% | 61.86% | 61.84% |
| Others | 7.21% | 6.23% | 13.84% | 8.76% | 10.47% | 10.4% | 10.08% | 9.99% | 9.83% | 8.02% | 8.16% | 8.18% |
| No. of Shareholders | 54458 | 89438 | 108137 | 108220 | 105838 | 109206 | 109080 | 107602 | 105804 | 104021 | 102252 | 101134 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 9 / 6 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1.18 | Sell |
| EMA (10) | 1.15 | Buy |
| SMA (20) | 1.09 | Buy |
| EMA (20) | 1.12 | Buy |
| SMA (50) | 1.07 | Buy |
| EMA (50) | 1.09 | Buy |
| SMA (100) | 1.12 | Buy |
| EMA (100) | 1.12 | Buy |
| SMA (200) | 1.18 | Sell |
| EMA (200) | 1.25 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 58.81 | Neutral |
| MACD (12,26,9) | 0.03 | Sell |
| Stochastic (14,3,3) | 54.35 | Neutral |
| ADX (14) | 27.72 | Buy |
| Williams %R (14) | -41.3 | Neutral |
| ATR (14) | 0.08 | High Volatility |
| ROC (12) | 17 | Buy |
| Stoch RSI (14) | 48.25 | Neutral |
| UO (7,14,28) | 36.89 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-08 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8af8dceb-821b-45e3-ba22-1804db4feb7a.pdf) |
| 2026-09-07 | [Notice Of The 34Th Annual General Meeting Of The Company To Be Held On September 29 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc9e34a3-59f0-404d-afb5-c653a19331a5.pdf) |
| 2026-09-07 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e957907-f52c-416a-9569-66403cbca111.pdf) |
| 2026-09-02 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0956300B_E184_4702_BDB1_9A2E11953479_103935.pdf) |
| 2026-09-02 | [Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Wednesday 02Nd September 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e2b2042-9e31-4efb-a150-f2c0460e5780.pdf) |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93d1d191-65de-484c-a387-40ee0b08e9cb.pdf) |
| 2026-09-02 | [Intimation Of Book Closure For The Purpose Of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77caee1a-a35f-4e39-977a-4b73d33cde00.pdf) |
| 2026-08-31 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=23050B33_014C_4F1E_98FB_E609FDBB59ED_120438.pdf) |
| 2026-08-28 | [Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday 02Nd September 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=810901dd-3983-4468-b933-ec43e3657680.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70f92eab-7cef-4423-84cd-64bc3153e9cd.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-11 | [Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended 30Th June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a32d87c9-bce7-42f0-94ef-d739c4d910c6.pdf) |
| 2026-05-21 | [Audited Standalone & Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended 31St March 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6bdfe94d-b791-42c2-bf9e-24d28da2911b.pdf) |
| 2026-02-09 | [Unaudited Standalone & Consolidated Financial Result Of The Company For The Quarter Ended December 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fb2a7f52-aa0f-415e-bec0-7ee9866d1640.pdf) |
| 2025-11-06 | [Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter & Half Year Ended 30Th September 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=15f17345-ebf5-45f4-91a4-a2170debc685.pdf) |
| 2025-08-07 | [Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended 30Th June 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70e237a7-bb19-4842-9054-1e325d91adad.pdf) |
| 2025-05-21 | [Audited Standalone & Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended 31St March 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=544030d9-480f-4a42-b0b6-8a8b5d1e1eba.pdf) |
| 2025-02-10 | [Result - Financial Results For The Quarter And Nine Months Ended December 31 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5fc903e-4b73-4f83-ab84-3e35bf4361a2.pdf) |
| 2024-11-12 | [Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d01541e3-2083-4780-b703-51b6cafe63fd.pdf) |
| 2024-08-13 | [Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended 30Th June, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=458fc408-adc1-407e-925b-916d90b89e02.pdf) |
| 2024-05-24 | [Audited Standalone & Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended 31St March, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9894daa5-79d7-48c6-b21b-f0a6723efa30.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - Rights issue Rs.4,845.05 lakh (allotment 21 Feb 2024); no deviation in proceeds utilization. | [Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 31St December, 2025. 9 Feb - Rights issue Rs.4,845.05 lakh (allotment 21 Feb 2024); no deviation in proceeds utilization.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/79232dec-574f-4a4f-9b30-de4d754ea6a1.pdf) |
| 9 Feb - Board approved unaudited standalone & consolidated Q3 (Dec 31, 2025) results; inventories reclassified; Rs.89.32 lakh decrease. | [Board Meeting Outcome for Outcome Of The Meeting Of Board Held On Monday, February 09, 2026. 9 Feb - Board approved unaudited standalone & consolidated Q3 (Dec 31, 2025) results; inventories reclassified; Rs.89.32 lakh decrease.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/96e621cc-a74f-4a6b-99fb-4d7fcd3eebad.pdf) |
| 8 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; no physical shares received for demat. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; no physical shares received for demat.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/497755de-ce4f-43d6-a6a0-6c4a6090ae12.pdf) |
| 29 Jan - Q3 revenue Rs5,722.44L; Q3 PAT Rs257.66L; 9M revenue Rs15,072.50L; approved 29-Jan-2026. | [Board Meeting Outcome for Results - Financial Results For The Quarter & Period Ended On 31.12.2025 29 Jan - Q3 revenue Rs5,722.44L; Q3 PAT Rs257.66L; 9M revenue Rs15,072.50L; approved 29-Jan-2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a2cd66ec-5d96-47f8-9455-ff81b7612564.pdf) |
| 28 Oct 2025 - Unaudited standalone Q2/H1 results ended 30 Sep 2025: revenue Rs5,161.49 lakh; PBT Rs300.46 lakh. | [Board Meeting Outcome for Results - Financial Results For The Quarter & Half Year Ended On 30Th September 2025. 28 Oct 2025 - Unaudited standalone Q2/H1 results ended 30 Sep 2025: revenue Rs5,161.49 lakh; PBT Rs300.46 lakh.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d0e11dfb-28e9-4a97-83a8-82e1adde2d39.pdf) |
| 26 Mar - Trading window closed Apr 1, 2026 until 48 hours post audited results for year ended Mar 31, 2026. | [Closure of Trading Window 26 Mar - Trading window closed Apr 1, 2026 until 48 hours post audited results for year ended Mar 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7edc6699-878b-4874-a37c-a51199ad3e9f.pdf) |
| 24 Mar - Independent Directors met 24-Mar-2026; reviewed board and chair performance and information flow; meeting 11:00–11:30. | [Outcome Of Separate Meeting Of Independent Directors Of The Company. 24 Mar - Independent Directors met 24-Mar-2026; reviewed board and chair performance and information flow; meeting 11:00–11:30.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/59febda2-50c5-4168-8e5a-4c5761f8759c.pdf) |
| 2 Feb - Board meeting on 09-Feb-2026 to approve unaudited standalone and consolidated results for quarter ended 31-Dec-2025. | [Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Monday, 09Th February, 2026. 2 Feb - Board meeting on 09-Feb-2026 to approve unaudited standalone and consolidated results for quarter ended 31-Dec-2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b1280d24-2b88-4b9c-85e1-e1a7599c355f.pdf) |
| 19 Jan - Board meeting on 29-Jan-2026 to approve standalone unaudited results for quarter/cumulative ended 31-Dec-2025. | [Board Meeting Intimation for Considering And Approving Unaudited Standalone Financial Results For The Quarter And Nine Months Ended On 31St December 2025. 19 Jan - Board meeting on 29-Jan-2026 to approve standalone unaudited results for quarter/cumulative ended 31-Dec-2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3bf8d4e2-183a-467b-b744-c1bf43d6cd4b.pdf) |
| 14 Apr - Genpharmasec says it is not a large corporate under SEBI debt framework as of 14 Apr 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 14 Apr - Genpharmasec says it is not a large corporate under SEBI debt framework as of 14 Apr 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/156c2a48-1770-4550-a2e0-657a6ff37e69.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/37cb8a8c-e50e-4032-9da3-34654a4b6586.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f36af69d-3fbb-4cc2-b4cf-e9fd6331311d.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b7b9fa82-18be-49d5-8c31-b393167caf49.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/302e4463-5314-4bdf-a81a-8474774e61c2.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cad98cee-458a-4069-8c1d-44129b92b20b.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/75ebc5ec-e371-4b84-9831-9c3f6f3a5b80.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/500220/73819500220.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/531592/76039531592.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/500220/69325500220.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/531592/71437531592.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:40:00.760Z.